Vidan Diagnostics Key Focus Remains on Implementing Its Strategy To Position Its Beta-Hydroxybutyrate Core Business in 2022

SAN ANTONIO, TEXAS — April 21, 2022 — Vidan Diagnostics, LLC, a U.S based supplier of in-vitro diagnostic products focused in the areas of diabetes, sepsis, heart disease & stroke, and anemia, announces its final results for 2021.

Record Revenue and Growth

Despite the effects of the Covid-19 pandemic on the diagnostics industry, 2021 was a year that delivered record revenue and growth. Vidan Diagnostics nearly doubled its annual revenue with an increase of 98% percent from a year-ago, and an all-time record. “We are pleased with our very strong business performance that drove an all-time revenue record,” said Gilbert Mejia, CEO of Vidan Diagnostics. “We are also fortunate to have developed a healthy pipeline of potential customers for our beta-hydroxybutyrate core business for sustainble growth in 2022,” added Mr. Mejia.

Beta-Hydroxybutyrate

Beta-hydroxybutyrate is the predominate ketone body produced during Diabetic Ketoacidosis, (DKA) It’s relative proportion in the blood, (78%) is greater than the other two ketones, acetoacetate, (20%) and acetone, (2%) and is therefore the best indicator of DKA. DKA is a serious condition that can lead to diabetic coma or even death.

Founded in 2018, Vidan Diagnostics LLC is a supplier of medical diagnostic products. It is focused on medical devices and reagents used for diagnosing and monitoring patients with conditions of diabetes, sepsis, anemia, heart disease and stroke. Vidan Diagnostics is dedicated to delivering proven and innovative products to all people in all places, in all aspects and stages of life with integrity and reliability. The company is headquartered in San Antonio, Texas.